Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms

Effects of Mutational Combinations on Philadelphia-Negative Myeloproliferative Neoplasms

Philadelphia-negative chronic myeloproliferative neoplasms

Chronic myeloproliferative diseases without the Philadelphia chromosome marker (Ph-), although first described 60 years ago, only became the subject of interest after the turn of the millennium. In 2001, the World Health Organization (WHO) defined the classification of this group of diseases and in 2008 they were renamed myeloproliferative neoplasms based on morphological, cytogenetic and molec...

Second malignancies in philadelphia-negative myeloproliferative neoplasms-single-center experience.

AIM The aim of this work was to retrospectively analyze patients with Philadelphia-negative myeloproliferative neoplasms through evaluation of frequency and characteristics of second malignancies (other than acute leukaemia and myelodysplastic syndrome). PATIENTS AND METHODS Records of 172 patients were reviewed; an analysis was performed on data from 66 patients treated with hydroxyurea, 105...

Molecular biology of Philadelphia-negative myeloproliferative neoplasms

Myeloproliferative neoplasms are clonal diseases of hematopoietic stem cells characterized by myeloid hyperplasia and increased risk of developing acute myeloid leukemia. Myeloproliferative neoplasms are caused, as any other malignancy, by genetic defects that culminate in the neoplastic phenotype. In the past six years, since the identification of JAK2V617F, we have experienced a substantial i...

Autoimmune Thyroid Disease in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms Treated with Interferon-Alpha

Objectives: Interferon-alpha (IFN-α) is increasingly being used in the treatment of the Philadelphia-negative chronic myeloproliferative neoplasms (MPNs). However, some 20% of patients discontinue treatment because of side effects, including thyroid dysfunction. Methods: This retrospective study reports patients with MPNs who developed autoimmune thyroid disease (AITD) during treatment with IFN...